Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071664 · ClinicalTrials.gov registry record · Phase 2
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT05071664 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 91 participants.
The verdict
NCT05071664, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.
Interventions
- DRUG Placebo
- DRUG Guselkumab
- DRUG Golimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05071664
The ClinicalTrials.gov registry entry for NCT05071664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05071664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05071664 about?
NCT05071664 is a clinical study titled "A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis". The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared wit...
What is the current status of trial NCT05071664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2021-10-25. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT05071664?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG), Golimumab (DRUG).
Who is sponsoring clinical trial NCT05071664?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.